Financial Comparison: Globus Medical (NYSE:GMED) & Xcorporeal (OTCMKTS:XCRP)

Xcorporeal (OTCMKTS:XCRPGet Free Report) and Globus Medical (NYSE:GMEDGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Insider and Institutional Ownership

95.2% of Globus Medical shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Xcorporeal and Globus Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xcorporeal 0 0 0 0 0.00
Globus Medical 0 4 9 2 2.87

Globus Medical has a consensus price target of $106.36, indicating a potential upside of 36.51%. Given Globus Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than Xcorporeal.

Earnings & Valuation

This table compares Xcorporeal and Globus Medical”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xcorporeal N/A N/A N/A N/A N/A
Globus Medical $2.94 billion 3.60 $537.87 million $4.30 18.12

Globus Medical has higher revenue and earnings than Xcorporeal.

Profitability

This table compares Xcorporeal and Globus Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xcorporeal N/A N/A N/A
Globus Medical 18.92% 13.46% 11.65%

Summary

Globus Medical beats Xcorporeal on 10 of the 10 factors compared between the two stocks.

About Xcorporeal

(Get Free Report)

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About Globus Medical

(Get Free Report)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Receive News & Ratings for Xcorporeal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xcorporeal and related companies with MarketBeat.com's FREE daily email newsletter.